Fluoxetine therapy in obese diabetic and glucose intolerant patients.

Author: Kutnowski M, Daubresse JC, Friedman H, Kolanowski J, Krzentowski G, Scheen A, Van Gaal L

Author affiliation: Hopital Universitaire Brugmann, Department of Internal Medicine, ULB, Brussels, Belgium.

Publication date & source: 1992.12, Int J Obes Relat Metab Disord., 16 Suppl 4:S63-6.

Publication type: Clinical Trial; Controlled Clinical Trial; Multicenter Study

A double-blind placebo-controlled trial was conducted, involving 97 obese diabetic and glucose intolerant patients receiving either 60 mg fluoxetine daily (47 patients) or a placebo (50 patients); a similar calorie-restricted diet was prescribed to all patients. Weight loss was significantly higher in the fluoxetine-treated patients, whose diabetic status improved. Drop-out rate was not significantly different for both groups of patients.